4-methoxy-3-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzaldehyde | 178610-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-methoxy-3-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzaldehyde
• 英文别名: 4-methoxy-3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzaldehyde
• CAS: 178610-66-7
• 化学式: C₁₉H₁₇NO₄
• 分子量: 323.348
• InChiKey: PAEATPXKBRWURL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  61.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-methoxy-3-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzaldehyde 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.5h， 以99%的产率得到4-methoxy-3-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl alcohol
  参考文献：
  名称：

  ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF

  摘要：

  公开号：

  EP1357115B1
• 作为产物：
  描述：

  4-(氯甲基)-5-甲基-2-苯基-1,3-恶唑 、 异香兰素 以to yield 4-methoxy-3-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzaldehyde, which的产率得到4-methoxy-3-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzaldehyde
  参考文献：
  名称：

  Oxazolidinedione derivatives, their production and use

  摘要：

  该化合物的中文翻译如下：2,4-噁唑烷二酮衍生物，其化学式为：##STR1## 其中，R代表可选取的取代的碳氢残基或杂环基；Y代表一个由--CO--，--CH(OH)--或--NR.sup.3--（其中R.sup.3代表可选取的取代的烷基）表示的基团；m为0或1；n为0、1或2；A代表C.sub.1-7双价脂肪族碳氢基团；R.sup.1代表氢或烷基；环E代表一个带有1或2个取代基的苯环；L和M分别代表氢，或L和M可选地结合成键；但需要注意的是，部分式：##STR2## 不包括式：##STR3## 其中，R'代表烷基；或其盐，具有降低血糖和血脂的优异作用。

  公开号：

  US05932601A1

文献信息

• Alkanoic acid derivatives process for their production and use thereof
  申请人：——

  公开号：US20040058965A1

  公开（公告）日：2004-03-25

  An alkanoic acid derivative useful as a prophylactic or therapeutic agent of diabetes mellitus, hyperlipidemia, impaired glucose tolerance and the like can be provided by a compound represented by the formula 1 wherein R 1 is an optionally substituted 5-membered aromatic heterocyclic group; X is a bond and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond and the like, ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n —Z 1 — (n is an integer of 1 to 8 and Z 1 is an oxygen atom and the like) and the like; ring B is a pyridine ring optionally further having 1 to 3 substituents, and the like; U is a bond and the like; W is a divalent hydrocarbon group having 1 to 20 carbon atoms; and R 3 is —OH and the like, provided that, when ring B is a benzene ring optionally further having 1 to 3 substituents, U should be a bond, or a salt thereof.

  一种可以用作糖尿病、高脂血症、糖耐量受损等预防或治疗剂的脂肪酸衍生物可以由以下式1所表示的化合物提供，其中R1是可选取代的5-成员芳香杂环基；X是键等；Q是具有1到20个碳原子的二价碳氢基团；Y是键等；环A是一种芳香环，可选择进一步具有1到3个取代基；Z是—（CH2）n—Z1—（n是1到8的整数，Z1是氧原子等）等；环B是吡啶环，可选择进一步具有1到3个取代基等；U是键等；W是具有1到20个碳原子的二价碳氢基团；R3是—OH等；但是，当环B是苯环，可选择进一步具有1到3个取代基时，U应为键，或其盐。
• 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07179823B1

  公开（公告）日：2007-02-20

  A compound of formula (I) F wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; x represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: —CO—, —CS—, —CR4(OR5)— or —NR6— wherein each of R4 and R6 represents a hydrogen atom or a hydrocarbon group which may be stubstituted, R5 represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: —SO—, —SO2—, —NR7—, —CONR7— or —NR7CO— wherein R7 represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group.

  化合物的式子为（I）F，其中R1代表一个可以被取代的碳氢基团或杂环基团；x代表一个键、一个氧原子、一个硫原子或者一个式子为：—CO—、—CS—、—CR4(OR5)—或—NR6—的基团，其中R4和R6分别代表一个氢原子或者一个可以被取代的碳氢基团，R5代表一个氢原子或者一个羟基的保护基团；m代表一个0到3的整数；Y代表一个氧原子、一个硫原子或者一个式子为：—SO—、—SO2—、—NR7—、—CONR7—或—NR7CO—的基团，其中R7代表一个氢原子或者一个可以被取代的碳氢基团；环A代表一个芳香环，可以有1到3个取代基；n代表一个1到8的整数；环B代表一个含氮的5元杂环，可以有一个烷基的取代基。
• 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1457490A1

  公开（公告）日：2004-09-15

  Use of a compound of the formula: wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR4(OR5)- or -NR6- wherein each of R4 and R6 represents a hydrogen atom or a hydrocarbon group which may be substituted, R5 represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO2-, -NR7-, -CONR7- or -NR7CO- wherein R7 represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group; X1 represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO2-, -O-SO2- or -NR16- wherein R16 represents a hydrogen atom or a hydrocarbon group which may be substituted; R2 represents a hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; W represents a bond or a divalent hydrocarbon residue having 1 to 20 carbon atoms; R3 represents a group of the formula: -OR8 (R8 represents a hydrogen atom or a hydrocarbon group which may be substituted) or -NR9R10 (each of R9 and R10, whether identical or not, represents a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; R9 and R10 may bind together to form a ring); or a salt thereof, for the manufacture of a pharmaceutical preparation for preventing or treating syndrome X.

  式化合物的用途： 其中 R1 代表可被取代的烃基或可被取代的杂环基； X 代表键、氧原子、硫原子或式中的基团：-其中 R4 和 R6 分别代表氢原子或可被取代的烃基，R5 代表氢原子或羟基的保护基团； m 代表 0 至 3 的整数； Y 代表氧原子、硫原子或式中的一个基团：-其中 R7 代表氢原子或可被取代的烃基； 环 A 代表芳香环，可进一步具有 1 至 3 个取代基； n 代表 1 至 8 的整数； 环 B 代表含氮 5 元杂环，可进一步被烷基取代； X1 代表键、氧原子、硫原子或式中的基团：-其中 R16 代表氢原子或可被取代的烃基； R2 代表氢原子、可被取代的烃基或可被取代的杂环基； W 代表键或具有 1 至 20 个碳原子的二价烃残基； R3 代表式中的一个基团：-OR8(R8代表氢原子或可被取代的烃基)或-NR9R10(R9和R10，无论是否相同，各自代表氢原子、可被取代的烃基、可被取代的杂环基或可被取代的酰基；R9和R10可结合在一起形成环)；或其盐、 用于制造预防或治疗 X 综合征的药物制剂。
• ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1357115B1

  公开（公告）日：2009-06-17
• 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGYLCEMIC AND HYPOLIPIDEMIC ACTIVITY
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1228067A1

  公开（公告）日：2002-08-07